ORIC Pharmaceuticals Inc.

October marks Breast Cancer Awareness Month, a time to honor the strength of patients, survivors, and families, and to reflect on the urgent need for continued progress in cancer research and treatment. At ORIC®, our “why” is to Overcome Resistance In Cancer, one of the greatest challenges in treatment today. By advancing science, we aim to bring new hope and lasting impact to people living with breast cancer and beyond. #BreastCancerAwareness #CancerResearch #MyWhyLBBC

The ORIC® team was proud to join the 2025 GO2 San Francisco Bay Area 5K Walk/Run. This event unites lung cancer survivors, caregivers, and supporters to raise awareness and funds for patient support and research with the goal to accelerate potential cures. Our dedication to the continued development of our EGFR/HER2 inhibitor, enozertinib (ORIC-114) for the potential treatment of non-small cell lung cancer is fueled by the voices, stories, and resilience of those affected by this disease. #GO2forLungCancer #LungCancerAwareness #CancerResearch 

On #WorldCancerResearchDay, we honor the scientists, physicians, and patients driving progress against cancer. At ORIC®, we are advancing our portfolio of innovative investigational oncology therapies to potentially Overcome Resistance In Cancer and deliver better outcomes for patients. Learn more: https://bit.ly/3Wd6EnK #CancerResearch #WCRD

This #HispanicHeritageMonth, we celebrate the rich history, culture, and contributions of Hispanic and Latino communities. At ORIC®, we are committed to fostering an inclusive environment where diverse voices, perspectives, and experiences drive innovation in science and our mission to Overcome Resistance In Cancer. #Inclusion #DiversityInSTEM #HispanicHeritage

Tomorrow at 1:25 p.m. ET, ORIC® President and Chief Executive Officer Jacob Chacko, M.D., and Chief Financial Officer Dominic Piscitelli will discuss the latest company updates in a fireside chat at the Baird 2025 Global Healthcare Conference. Listen to the live or archived discussion here: https://bit.ly/3VxP4tj

ORIC® President and Chief Executive Officer Jacob Chacko, M.D., and Chief Financial Officer Dominic Piscitelli will be available for investor one-on-one meetings at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025. If you're participating, we welcome the opportunity to connect.

This #ProstateCancer Awareness Month, we stand with the millions of men and families impacted by this deadly disease globally. At ORIC®, we are advancing clinical trials for ORIC-944, our potential best-in-class PRC2 inhibitor to treat metastatic castration-resistant prostate cancer (mCRPC). Our mission to Overcome Resistance In Cancer is driven by the urgency to bring hope and better options to patients who need them most.

Tomorrow at 8:35 a.m. ET, ORIC® President and Chief Executive Officer Jacob Chacko, M.D., and Chief Financial Officer Dominic Piscitelli will discuss the latest company updates in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference 2025 Listen to the live or archived discussion here: https://bit.ly/3VxP4tj

ORIC® President and Chief Executive Officer Jacob Chacko, M.D., and Chief Financial Officer Dominic Piscitelli will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025, at 2:15 p.m. ET. Listen to the live or archived discussion here: https://bit.ly/3VxP4tj

Don’t miss ORIC® President and Chief Executive Officer Jacob Chacko, M.D., and Chief Financial Officer Dominic Piscitelli discuss the latest company updates in a fireside chat at Citi's 2025 Biopharma Back to School Summit. Listen to the live discussion on Wednesday, September 3, 2025, at 4:00 p.m. ET, or the archived replay here: https://bit.ly/3VxP4tj